With the rationale that patients SF3B1mut cells would still express 40% of COASY enzyme, in our erythroid differentiation model we treated primary CD34+ patient cells (isolated from a patient with MDS-RS or healthy donor) with upstream substrates COASY, vitamin B5, or its downstream by-product succinyl-CoA (Fig 6A). This evidence concerns the gene CD34 and myelodysplastic syndrome.